Stock comparison
Intellia Therapeutics, Inc. is 1.4x more valuable than Anbio Biotechnology by market capitalization ($2.16 B vs $1.50 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
NTLA is larger
Intellia Therapeutics, Inc. is 1.4x more valuable than Anbio Biotechnology by market capitalization ($2.16 B vs $1.50 B).
Market value leader
NTLA
Intellia Therapeutics, Inc. is 1.4x more valuable than Anbio Biotechnology by market capitalization ($2.16 B vs $1.50 B).
Revenue leader
NTLA
NTLA: $67.67M vs NNNN: $8.65M.
Profit leader
NNNN
NTLA: -$412.69M vs NNNN: $6.40M.
Margin leader
NNNN
NTLA: -609.9% vs NNNN: 74.1% net margin.
| Metric | NTLA | NNNN |
|---|---|---|
| Market cap | $2.16 B | $1.50 B |
| US-listed rank | #2076 | #2355 |
| Revenue (latest FY) | $67.67M | $8.65M |
| Net income (latest FY) | -$412.69M | $6.40M |
| Net margin | -609.9% | 74.1% |
| P/E (trailing FY) | - | 234.2x |
| SEC filings | 679 | 40 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Intellia Therapeutics, Inc. is 1.4x more valuable than Anbio Biotechnology by market capitalization ($2.16 B vs $1.50 B).
In their latest fiscal years, Intellia Therapeutics, Inc. reported $67.67M in revenue while Anbio Biotechnology reported $8.65M.
Full pages: Intellia Therapeutics, Inc. and Anbio Biotechnology, or browse the full rankings.